Free tool
FAERS Monitor: Eligard Kit
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021379 or its brand name (Eligard Kit, Leuprolide Acetate). Reports on generic versions are filed under their own applications.
Reports
53,725
Serious
24,534
46% of reports
Hospitalization
8,120
Death reported
9,258
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- intercepted product preparation error9,289
- syringe issue7,756
- death6,647
- hot flush6,332
- device leakage6,244
- wrong technique in product usage process5,489
- injection site pain4,235
- fatigue3,553
- prostatic specific antigen increased1,955
- asthenia1,692
- intentional product use issue1,661
- prostate cancer1,517
- off label use1,498
- fall1,455
- drug ineffective1,324
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 97 |
| 2005 | 114 |
| 2006 | 109 |
| 2007 | 146 |
| 2008 | 375 |
| 2009 | 202 |
| 2010 | 275 |
| 2011 | 303 |
| 2012 | 417 |
| 2013 | 188 |
| 2014 | 291 |
| 2015 | 847 |
| 2016 | 2,118 |
| 2017 | 1,624 |
| 2018 | 1,701 |
| 2019 | 2,572 |
| 2020 | 4,926 |
| 2021 | 6,196 |
| 2022 | 7,124 |
| 2023 | 7,038 |
| 2024 | 8,802 |
| 2025 | 5,866 |
| 2026 | 2,394 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,000,434 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intercepted product preparation errorSignal | 9,289 | 1197.9 | 1150.8 | 2,734,393 |
| syringe issueSignal | 7,756 | 310.5 | 301.8 | 1,334,510 |
| device leakageSignal | 6,244 | 65.7 | 64.0 | 341,168 |
| prostatic specific antigen increasedSignal | 1,955 | 64.6 | 61.6 | 105,015 |
| hot flushSignal | 6,332 | 35.8 | 35.0 | 196,969 |
| wrong technique in product usage processSignal | 5,489 | 10.9 | 10.6 | 48,327 |
| intentional product use issueSignal | 1,661 | 7.5 | 7.2 | 9,287 |
| prostate cancerSignal | 1,517 | 7.5 | 7.1 | 8,420 |
| injection site painSignal | 4,235 | 5.5 | 5.3 | 15,464 |
| deathSignal | 6,647 | 3.0 | 3.0 | 9,390 |
| fatigue | 3,553 | 1.8 | 1.7 | 1,280 |
| asthenia | 1,692 | 1.8 | 1.7 | 568 |
| fall | 1,455 | 1.7 | 1.6 | 438 |
| off label use | 1,498 | 0.7 | 0.6 | 255 |
| drug ineffective | 1,324 | 0.4 | 0.4 | 1,325 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.